Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Renal Insufficiency

被引:32
|
作者
Hsu, Chia-Yang [3 ]
Huang, Yi-Hsiang [4 ]
Su, Chien-Wei [5 ]
Chiang, Jen-Huey [2 ,5 ]
Lin, Han-Chieh [5 ]
Lee, Pui-Ching
Lee, Fa-Yauh [5 ]
Huo, Teh-Ia [1 ,6 ]
Lee, Shou-Dong [5 ]
机构
[1] Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol, Taipei 112, Taiwan
[2] Taipei Vet Gen Hosp, Dept Radiol, Taipei 112, Taiwan
[3] Natl Yang Ming Univ Hosp, Dept Med, Yilan, Taiwan
[4] Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 112, Taiwan
[5] Natl Yang Ming Univ, Sch Med, Fac Med, Taipei 112, Taiwan
[6] Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 112, Taiwan
关键词
contrast medium-induced nephropathy; hepatocellular carcinoma; liver cirrhosis; renal insufficiency; transarterial chemoembolization; RISK-FACTORS; INDUCED NEPHROPATHY; STAGING SYSTEMS; CLINICAL-COURSE; FAILURE; DISEASE; MODEL; CIRRHOSIS; STRATEGIES; DIAGNOSIS;
D O I
10.1097/MCG.0b013e3181c88235
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Renal dysfunction is often present in patients with cirrhosis and hepatocellular carcinoma (HCC). Acute renal failure (ARF) may occur after transarterial chemoembolization (TACE) owing to radiocontrast agent. This study investigated the incidence and risk factors of ARF and prognostic predictors in HCC patients with preexisting renal insufficiency undergoing TACE. Methods: A total of 566 HCC patients undergoing TACE were enrolled. Renal insufficiency was defined as an estimated glomerular filtration rate less than 60 mL/min/1.73m(2). Results: In a mean follow-up duration of 18 +/- 16 months, 231 (40.8%) patients undergoing TACE died. Renal insufficiency that was present in 134 (23.7%) patients at baseline, independently predicted a poor prognosis in the Cox proportional hazards model [risk ratio (RR): 1.47, P = 0.012]. Of them, 13 (10%) and 6 (5%) patients had transient and prolonged ARF after TACE, respectively. Post-TACE gastrointestinal bleeding [odds ratio (OR): 16.54, P = 0.001] and higher Cancer of the Liver Italian Program (CLIP) scores (>= 2; OR: 4.22, P = 0.02) were independent risk factors for ARF in the multivariate logistic regression analysis. In the Cox model, prolonged ARF (RR: 3.28, P < 0.001) and higher CLIP scores (>= 2; RR: 2.13, P < 0.001) were independent poor prognostic predictors for HCC patients with renal insufficiency receiving TACE. Conclusions: Gastrointestinal bleeding and higher CLIP scores are associated with the development of ARF in patients with HCC and renal insufficiency undergoing TACE. Higher CLIP scores and renal insufficiency, either preexisting before TACE or as a complication of TACE, are poor prognostic predictors in HCC patients receiving TACE.
引用
收藏
页码:E171 / E177
页数:7
相关论文
共 50 条
  • [21] Preresection transarterial chemoembolization for hepatocellular carcinoma
    Tin, Sim
    Wiwanitkit, Viroj
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2015, 34 (02) : 188 - 188
  • [22] Predictors of Mortality in Patients with Hepatocellular Carcinoma undergoing Transarterial Chemoembolization
    Barman, Pranab
    Sharma, Pratima
    Krishnamurthy, Venkat
    Willatt, Jonathon
    McCurdy, Heather
    Moseley, Richard H.
    Su, Grace L.
    HEPATOLOGY, 2013, 58 : 1271A - 1271A
  • [23] Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization
    Xiao, Jun
    Li, Guojian
    Lin, Shuhan
    He, Ke
    Lai, Hao
    Mo, Xianwei
    Chen, Jiansi
    Lin, Yuan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (03): : 1114 - 1123
  • [24] Is transarterial chemoembolization beneficial for patients with diffuse infiltrative hepatocellular carcinoma?
    Tsung-Hsing Hung
    Chen-Chi Tsai
    Chung-Chi Lin
    Hsing-Feng Lee
    Chi-Jen Chu
    Han-Chieh Lin
    Hepatology International, 2013, 7 : 676 - 682
  • [25] Is transarterial chemoembolization an option for all patients with unresectable hepatocellular carcinoma?
    Burroughs, Andrew
    Samonakis, Dirnitrios
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2004, 1 (02): : 78 - 79
  • [26] Selective and sequential transarterial chemoembolization: Survival in patients with hepatocellular carcinoma
    Antoch, Gerald
    Roelle, Grit
    Ladd, Susanne C.
    Kuehl, Hilmar
    Heusner, Till A.
    Sotiropoulos, Georgios C.
    Hilgard, Philip
    Forsting, Michael
    Verhagen, Ruediger
    EUROPEAN JOURNAL OF RADIOLOGY, 2012, 81 (09) : 2290 - 2297
  • [27] Transarterial Chemoembolization with Miriplatin plus Epirubicin in Patients with Hepatocellular Carcinoma
    Tawada, Akinobu
    Chiba, Tetsuhiro
    Ooka, Yoshihiko
    Kanogawa, Naoya
    Saito, Tomoko
    Motoyama, Tenyu
    Ogasawara, Sadahisa
    Suzuki, Eiichiro
    Kanai, Fumihiko
    Yoshikawa, Masaharu
    Yokosuka, Osamu
    ANTICANCER RESEARCH, 2015, 35 (01) : 549 - 554
  • [28] Transarterial chemoembolization in patients with hepatocellular carcinoma: who are the best candidates?
    Bouattour, Mohamed
    Abdel-Rehim, Mohamed
    Goutte, Nathalie
    Vullierme, Marie-Pierre
    Faivre, Sandrine
    Raymond, Eric
    Valla, Dominique
    Castera, Laurent
    Vilgrain, Valerie
    Farges, Olivier
    HEPATOLOGY, 2012, 56 : 449A - 450A
  • [29] Is transarterial chemoembolization an option for all patients with unresectable hepatocellular carcinoma?
    Andrew Burroughs
    Dimitrios Samonakis
    Nature Clinical Practice Gastroenterology & Hepatology, 2004, 1 : 78 - 79
  • [30] Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma
    Guo, Jingjing
    Wang, Saixia
    Han, Yujing
    Jia, Zhongyuan
    Wang, Runchao
    ONCOLOGY LETTERS, 2021, 22 (01)